1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Bladder cancer

Enfortumab vedotin with pembrolizumab for first-line treatment of unresectable or metastatic urothelial cancer who are eligible for platinum-containing chemotherapy [ID6332]

In development [GID-TA11233] Expected publication date: 04 June 2025

  • Project information
  • Project documents

NIHRIO BN: Microsoft Word - 29564 (TSID_10556) Enfortumab vedotin+Pembrolizumab for UC V1.0 NOV22 NON CONF (nihr.ac.uk)